Global Cytotoxic Drugs Contract Manufacturing Market, by Production Scale (Industrial Scale, Pilot Scale, and Laboratory Scale), by Form (Liquid, and Solid), by Product Type (Oral and Intravenous), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 6,285.2 million in 2018, and is expected to exhibit a CAGR of 9.1% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Governments in emerging economies such as India are focusing on initiatives to increase domestic production. For instance, in August 2017, according to the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers of government of India proposed 'peak customs duty' and suggested setting up of bulk drug parks to increase domestic production. Furthermore, rapid growth in the pharmaceutical industry in the Asia Pacific region is expected to propel growth of cytotoxic drug contract manufacturing market in the Asia Pacific region during the forecast period. For instance, in September 2019, according to the Indian Brand Equity Foundation (IBEF), India pharmaceutical industry is expected to reach US$ 55 Bn by 2020.

Increasing investment by the market players, in order to expand their service and product offerings is expected to boost growth of the cytotoxic drugs contract manufacturing market over the forecast period. For instance, in October 2017, Lonza Group established Lonza Collaborative Innovation Center (CIC) in new Life Science Park in Haifa, Israel. With this, Lonza aims to accelerate leading R&D projects across Lonza's Pharma & Biotech segment, and tap into potentially transformative biological and manufacturing capabilities.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/cytotoxic-drugs-contract-manufacturing-market-3175

Browse 38 Market Data Tables and 27 Figures spread through 193 Pages and in-depth TOC on ‘Cytotoxic Drugs Contract Manufacturing Market’- Global Forecast to 2027, by Production Scale (Industrial Scale, Pilot Scale, and Laboratory Scale), by Form (Liquid, and Solid), by Product Type (Oral and Intravenous), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

North America is expected to dominate cytotoxic drugs contract manufacturing market over the forecast period, owing to adoption of growth strategies such as product launches, investments, facility expansion by the market players in the region to expand their market presence. For instance, in 2016, Cambrex, a leading small molecule API contract manufacturer expanded its facility at Iowa, Charles City-based manufacturing site, adding 1,000- and 4,000 gallon glass-lined reactors in 7,500-square-foot plant.

Moreover, market players are focused on collaboration and acquisition strategies to expand their market presence and enhance facility in the region, which is expected to drive growth of the market over the forecast period. For instance, in November 2017, CordenPharma International, a contract provider of both small-molecule APIs and drug products acquired a Hospira Boulder facility from Pfizer Inc., a 54,000-square-foot API manufacturing facility located in Colorado, U.S. to build its capabilities in high-potency manufacturing. According to the expansion strategy, the new facility specializes in development, scale-up, optimization, and production of highly potent and cytotoxic/cytostatic APIs from development to commercialization stage.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3175

Key Takeaways of the Cytotoxic Drugs Contract Manufacturing Market:

The global cytotoxic drugs contract manufacturing market is expected to exhibit a CAGR of 9.1% over the forecast period, owing to increasing adoption of collaboration and acquisition strategies by key players and rising trend of contact manufacturing. Contract development and manufacturing organizations (CDMOs) play a vital role in expediting development of innovative small molecule drug candidates, as these important development activities are often achieved through outsourcing partnerships with CDMOs

Among form, liquid segment held dominant position in the cytotoxic drugs contract manufacturing market in 2018, owing to adoption of expansion strategies by the market players. For instance, in April 2018, STA Pharmaceutical, a subsidiary of WuXi AppTec, signed an investment agreement with the Government of Shanghai, to build a new research & development (R&D) center for APIs and intermediates located next to the company’s existing Jinshan drug-substance manufacturing site.

Among product type, intravenous segment held dominant position in the cytotoxic drugs contract manufacturing market in 2018, owing to companies focusing on expansion of their manufacturing facilities for production of sterile injectable and API, in order to increase client base and cater to their demand. For instance, in March 2017, Piramal Pharma Solutions expanded manufacturing capabilities in Lexington, U.S. The new facility includes installation of a new high-speed vial filling line, expansion of the state-of-the art laboratories, and associated utility support.

Companies operating in the global cytotoxic drugs contract manufacturing market include Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma International, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3175

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737